Navigation Links
2 Cleveland Clinic researchers honored for contribution to science
Date:11/25/2013

Monday, Nov. 25, 2013, Cleveland: Cleveland Clinic researchers Richard A. Padgett, Ph.D., and Edward F. Plow, Ph.D., have been named Fellows of the American Association for the Advancement of Science (AAAS). This year's AAAS Fellows will be formally announced in the AAAS News & Notes section of the journal Science on Nov. 29, 2013.

Dr. Padgett, who works in the Department of Molecular Genetics at the Lerner Research Institute, was elected as an AAAS Fellow for distinguished contributions to the field of RNA processing, particularly in the areas of RNA splicing, the diversity of splicing mechanisms, and connections with disease.

RNA, or ribonucleic acid, is a nucleic acid present in all living cells that translates the genetic code (DNA) into proteins. RNA splicing is the processing of RNA to remove portions that do not encode proteins. Many diseases are either caused by or associated with mistakes in the splicing process or mutations in the splicing machinery. Dr. Padgett's research aims to understand how these errors in RNA splicing lead to disease, such as cancer, and how the errors can be corrected.

Dr. Plow, Department Chair of Molecular Cardiology at the Lerner Research Institute, and The Robert C. Tarazi, M.D., Endowed Chair in Heart and Hypertension Research, is being honored as an AAAS Fellow for distinguished contributions to vascular biology, particularly for elucidating mechanisms of platelets, integrins, and plasminogen, and outstanding services to the cardiovascular community.

Dr. Plow's research involves dissecting the cellular mechanisms underlying hypertension and heart disease. Specifically, he studies the role of integrins, a type of cell adhesion molecule involved in blood coagulation, in cardiovascular disease. He also recently discovered that the blood protein plasminogen, which has long been associated with coronary artery disease, and a related enzyme are essential in the formation of foam cells-- a hallmark of advanced atherosclerosis, or hardening of the arteries.

Election as an AAAS Fellow is an honor bestowed upon AAAS members by their peers. This year 388 members have been awarded this honor by AAAS because of their scientifically or socially distinguished efforts to advance science or its applications.


'/>"/>

Contact: Laura Ambro
ambrol@ccf.org
216-636-5876
Cleveland Clinic
Source:Eurekalert

Related biology news :

1. Cleveland Clinic researchers receive $5 million grant to discover novel pathways to heart disease
2. Cleveland Clinic develops clinical screening program for no.1 genetic cause of colon cancer
3. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
4. Cleveland Clinic researchers discover new link between heart disease and red meat
5. Cleveland Clinic research shows gut bacteria byproduct predicts heart attack and stroke
6. Cleveland Clinics 2013 Obesity Summit explores causes, prevention and treatment of obesity
7. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
8. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
9. New clinical trial explores novel noninvasive colon cancer screening test
10. Genzyme/ACMG Foundation Genetics Training Award in Clinical Biochemical Genetics announced
11. FirstMark Exhibiting at the Inaugural Atlanta Clinical Cardiology Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... YORK , Feb. 2, 2016 ... of the bioinformatic market by reviewing the recent ... enabled tools that drive the field forward. Includes ... to: Identify the challenges and opportunities that ... providers and software solution developers, as well as ...
(Date:2/2/2016)... Feb. 2, 2016  Based on its recent ... Sullivan recognizes US-based Intelligent Retinal Imaging Systems (IRIS) ... Award for New Product Innovation. IRIS, a prominent ... North America , is poised to set ... diabetic retinopathy market. The IRIS technology presents superior ...
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of ... ended December 31, 2015. --> ... increased 2 percent compared to the comparable quarter last year to ... was $35.0 million, or $0.93 per diluted share. ... first quarter of fiscal 2016 grew 9 percent over the prior ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... , February 4, 2016 - New FDA action ... - New FDA action date of July 22, ... July 22, 2016   - ... in the past decade indicated for the treatment of signs and symptoms of ... has the potential to be the only product approved in the U.S. in ...
(Date:2/4/2016)... -- Beike Biotechnology, the Shenzhen ... in late 2015 to mark their successful combined efforts ... --> --> The signing, ... Therapy" was hosted by the Shenzhen Cell Bank and ... Beike Biotechnology Co., Ltd. Shenzhen,s ...
(Date:2/4/2016)... 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... to be held February 8-9, 2016, at the Waldorf ... Growth & Healthcare Conference, taking place in ... James Sapirstein , Chief Executive Officer of ContraVir, ...
(Date:2/4/2016)... 2016 Strasbourg, France , ... --> Strasbourg, France , to the US ... is pleased to announce that it acted as an advisor ... in Strasbourg, France , to the US ... --> Transgene (Euronext: TNG), a member of ...
Breaking Biology Technology: